Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.

Drugs - 1 Aug 2015

Bauer Sebastian, Joensuu Heikki

Abstract excerpt

Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability. Imatinib-resistant advanced GIST continues to pose a therapeutic challenge, likely due to the frequent presence of multiple mutations that confer drug resistance. Sunitinib and regorafenib are approved as second- and third-line agents,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Discovery
Share to Drugs, Investigational
Share to Forecasting

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Neoplasms

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Molecular Targeted Therapy

Share to Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 26187774
DOI: 10.1007/s40265-015-0440-8
PMCID: PMC4532715

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.PMID 26187774Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumour.Semantic proximity Read ↗

Translational insights into gastrointestinal stromal tumor and current clinical advances.Semantic proximity Read ↗

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

New targets and therapies for gastrointestinal stromal tumors.Semantic proximity Read ↗

Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease.Semantic proximity Read ↗

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.Semantic proximity Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions.Semantic proximity Read ↗

New treatment strategies for advanced-stage gastrointestinal stromal tumours.Semantic proximity Read ↗

Gastrointestinal stromal tumors (GISTs): from science to targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.